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Abstract
Background: Inability to control autoimmunity is the primary barrier to developing a cure for type 1 diabetes
(T1D). Evidence that human cord blood-derived multipotent stem cells (CB-SCs) can control autoimmune responses
by altering regulatory T cells (Tregs) and human islet b cell-specific T cell clones offers promise for a new approach
to overcome the autoimmunity underlying T1D.
Methods: We developed a procedure for Stem Cell Educator therapy in which a patient’s blood is circulated
through a closed-loop system that separates lymphocytes from the whole blood and briefly co-cultures them with
adherent CB-SCs before returning them to the patient’s circulation. In an open-label, phase1/phase 2 study,
patients (n = 15) with T1D received one treatment with the Stem Cell Educator. Median age was 29 years (range:
15 to 41), and median diabetic history was 8 years (range: 1 to 21).
Results: Stem Cell Educator therapy was well tolerated in all participants with minimal pain from two
venipunctures and no adverse events. Stem Cell Educator therapy can markedly improve C-peptide levels, reduce
the median glycated hemoglobin A1C (HbA1C) values, and decrease the median daily dose of insulin in patients
with some residual b cell function (n = 6) and patients with no residual pancreatic islet b cell function (n = 6).
Treatment also produced an increase in basal and glucose-stimulated C-peptide levels through 40 weeks. However,
participants in the Control Group (n = 3) did not exhibit significant change at any follow-up. Individuals who
received Stem Cell Educator therapy exhibited increased expression of co-stimulating molecules (specifically, CD28
and ICOS), increases in the number of CD4
+CD25
+Foxp3
+ Tregs, and restoration of Th1/Th2/Th3 cytokine balance.
Conclusions: Stem Cell Educator therapy is safe, and in individuals with moderate or severe T1D, a single
treatment produces lasting improvement in metabolic control. Initial results indicate Stem Cell Educator therapy
reverses autoimmunity and promotes regeneration of islet b cells. Successful immune modulation by CB-SCs and
the resulting clinical improvement in patient status may have important implications for other autoimmune and
inflammation-related diseases without the safety and ethical concerns associated with conventional stem cell-based
approaches.
Trial registration: ClinicalTrials.gov number, NCT01350219.
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In Type 1 diabetes (T1D), autoimmune destruction of
pancreatic islet b cells reduces an individual’s ability to
regulate blood glucose, ultimately resulting in poor
blood circulation, heart disease, stroke, infection, kidney
failure, and often premature death. Each day, millions of
patients with T1D receive insulin injections to survive,
but these injections do nothing to address the underly-
ing T cell-mediated autoimmune dysfunction. For the
past 25 years, attempts to address the underlying auto-
immunity have been unsuccessful [1] due to the polyclo-
nal nature of the autoimmune response and the global
challenges of immune regulation in T1D patients [1-5].
Combinations of individual approaches have been pro-
posed to address these challenges [2,6-8], but adherence
to these approaches will be complicated and costly.
Alternative approaches are needed. Stem cells have been
touted as a means of replacing lost pancreatic islet b
cells and curing T1D, but this approach is doomed in
the absence of a treatment for the underlying autoim-
mune response.
While traditional stem cell therapy is not likely to be
effective for long-term treatment of T1D, recent studies
suggest that alternative approaches using stem cells may
overcome the autoimmune component of the disease.
Human cord blood-derived stem cells (CB-SCs) and
mesenchymal stem cells have been shown to modulate
immune activity in vitro [9-13]. Subsequent studies have
demonstrated that CB-SCs can be used to alter immune
function and improve markers of T1D in nonobese dia-
betic mice (NOD) [14], and CB-SCs have been shown to
modulate the immune function of T1D patient-derived
islet b cell-specific pathogenic T cell clones in co-culture
[9]. Studies in animal models also suggest that CB-SC
treatment may allow the patient to regenerate the native
population of islet b cells without stem cell transplantation
[9,14,15]. To translate these findings into a clinically feasi-
ble therapy, we developed a novel process to re-educate a
patient’s lymphocytes through co-culture with CB-SCs. If
shown to be safe and effective, immune modulation by
CB-SCs has the potential to address T1D and other auto-
immune diseases while reducing risk to the donor, mini-
mizing ethical concerns, and avoiding graft-versus-host
disease [9].
Methods
Patients
T1D subjects receiving care through the Section of
Endocrinology at the General Hospital of Jinan Military
Command (Jinan, Shandong, China) were enrolled in a
phase 1/phase 2, open-label clinical trial conducted from
October 2010 through January 2011. With oversight
from a planning committee, the principal investigator
designed the trial and received ethical approval for the
clinical treatment protocol and consent form from the
General Hospital of Jinan Military Command (Jinan,
Shandong, China) and ethical approval for the in vitro
study protocol and consent form from the University of
Illinois at Chicago Institutional Review Board. Written
informed consent was obtained from each participant.
The trial was conducted with 15 subjects with estab-
lished T1D (mean duration: 8.5 ± 6.4 years). Patients
were qualified for enrollment if they met the 2010 diag-
nosis standards of the American Diabetes Association
and a blood test confirmed the presence of at least one
autoantibody to pancreatic islet b cells. Exclusion cri-
teria included clinically significant liver, kidney, or heart
disease; pregnancy; immunosuppressive medication; viral
diseases; or diseases associated with immunodeficiency.
Stem Cell Educator design
In previous studies we isolated multipotent cord blood
stem cells (CB-SCs) from human cord blood [16]. The
CB-SCs display embryonic cell markers (for example,
transcription factors OCT-4 and Nanog, stage-specific
embryonic antigen (SSEA)-3 and SSEA-4) and leukocyte
common antigen CD45, but they are negative for blood
cell lineage markers [9,16]. We identified a hydrophobic
material from FDA-approved (USP Class VI) Petri dishes
that tightly binds CB-SCs without interfering with their
immune modulating capability. We designed a chamber
for co-culture of lymphocytes and CB-SCs that includes
nine discs of the material with adherent CB-SCs sand-
wiched between a top cover plate and a bottom collecting
plate (Figure 1). The device was manufactured in a Class
100 K clean room and gamma-irradiated prior to intro-
ducing CB-SCs [16]. In the Stem Cell Educator, lympho-
cytes separated from a patient’sb l o o da r es l o w l yp a s s e d
through the stacked discs of material with adherent CB-
SCs and lymphocytes collected through a hole in the bot-
tom plate are returned to the patient. The materials used
to produce the device are approved for in vivo use
according to the United States Pharmacopeia (that is,
Grade Class VI Plastic).
CB-SC culture
Human cord blood units derived from healthy donors
were purchased from the Maternal and Child Health
Hospital (Jinan, Shandong, China). All cord blood sam-
ples were screened for alanine aminotransferase and
pathogenic antigen antibodies (including anti-HCV, anti-
HBsAg, anti-HIV, and anti-syphilis Abs), and only patho-
gen-free cord blood units were used for isolating CB-SCs.
Human cord blood-derived stem cells (CB-SC) were gen-
erated as previously described with the following modifi-
cations [14,16]. Cord blood mononuclear cells were
plated in serum-free culture medium (Lonza, Walkers-
ville, MD) and incubated at 37°C, in 8% CO2. After 2 to 3
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were prepared for clinical trial. Endotoxin level was
< 0.05 EU/ml.
Treatment and follow-up
Twelve participants received a single treatment with the
Stem Cell Educator (Tianhe Stem Cell Biotechnology
®,
Jinan, China), and three received a single treatment with
the Stem Cell Educator without adherent CB-SCs (that is,
sham or process-only control) (Figure 1). A 16-gauge IV
needle was placed in the left (or right) median cubital
vein, and the patient’s blood was passed through a Blood
Cell Separator MCS+ (Haemonetics
®, Braintree, MA, US)
at 35 mL/min for 6 to 7 hours to isolate lymphocytes in
accordance with the manufacturer’s recommended proto-
col. The collected lymphocytes were transferred into the
device for exposure to allogeneic CB-SCs (or process con-
trol without CB-SCs), and other blood components were
returned to the patient. After 2 to 3 hours in the device,
lymphocytes were returned to the patient’s circulation via
a dorsal vein in the hand under gravity flow control (2 to 3
mL/min) with physiological saline. Approximately 10,000
mL of blood was processed during the procedure resulting
in approximately two repeated educations for the lympho-
cyte fraction. Patients were hospitalized for two days to
monitor temperature and conduct routine laboratory
blood tests for adverse reactions following treatment.
Follow-up visits were scheduled 4, 12, 24, and 40 weeks
after treatment for clinical assessments and laboratory
tests (Additional file 1).
Study end points
The primary study end points were: 1) feasibility of the
Stem Cell Educator therapy; 2) safety of the therapy
through 12 weeks post treatment; and 3) preliminary eva-
luation of the efficacy of the therapy for improving b cell
function through 24 weeks. Pancreatic islet b cell function
was assessed by measuring basal and glucose-stimulated
C-peptide production over time, as described elsewhere
[17,18]. Metabolic control was monitored throughout the
study. The secondary study end point was evidence of the
efficacy of the therapy in modulating autoimmunity. Base-
line blood samples were collected prior to Stem Cell Edu-
cator therapy. Detailed descriptions of the methods are
included in the Supplementary Appendix.
Statistics
An intention-to treat approach was used, with 12 of 15
patients undergoing Stem Cell Educator therapy and the
remaining 3 patients undergoing sham therapy without
CB-SCs in the Educator. All patients were included in the
safety analyses. The primary efficacy end point was the
change in C-peptide secretion between baseline and fol-
low-up.
Stem Cell Educator
Blood Cell Separator
Transfer
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Figure 1 Overview of Stem Cell Educator therapy. A T1D participant (left) is connected to a Blood Cell Separator (right) and the Stem Cell
Educator (bottom center) to form a closed system. Lymphocytes isolated from the T1D participant by the Blood Cell Separator travel through
the Stem Cell Educator where they come in contact with CB-SCs attached to the interior surfaces of the device. Educated lymphocytes are
returned to the patient’s blood circulation. CB-SCs, cord blood stem cells; T1D, type 1 diabetes.
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Feasibility and safety of Stem Cell Educator therapy
Fifteen T1D patients were enrolled (baseline characteris-
tics presented in Table 1). Median age was 29 years
(range: 15 to 41), and median diabetic history was 8 years
(range: 1 to 21). Participants were randomly assigned to
receive Stem Cell Educator therapy (n = 12) or sham ther-
apy (n = 3). Each participant received one treatment.
Based on fasting C-peptide levels (a by-product of insulin
biosynthesis, as an indicator for islet b cell function), parti-
cipants in the treatment group were characterized as hav-
ing moderate T1D with some residual b cell function (n =
6, Group A) or severe T1D with no residual pancreatic
islet b cell function (n = 6, Group B) (Table 1). All Control
Group participants had moderate T1D.
No participants experienced any significant adverse
events during the course of treatment. Most patients
experienced mild discomfort during venipuncture and
some soreness of the arm during apheresis, but discom-
fort and soreness resolved quickly following the conclu-
sion of the procedure. Twenty-four hours post treatment,
no significant difference was noted in white blood cell
counts relative to baseline (total white blood cell count:
6.95 × 10
9/L ± 1.98 versus 6.39 × 10
9/L ± 1.72, P=0.38;
granulocytes: 3.79 × 10
9/ L±1 . 4 3v e r s u s3 . 6 6×1 0
9/L ±
1.05, P=0.77; lymphocytes: 2.31 × 10
9/L ± 0.9 versus
2.08 × 10
9/L ± 0.67, P=0.40; monocytes: 0.49 × 10
9/L ±
0.13 versus 0.46 × 10
9/L ± 0.10, P=0.48). Participants’
body temperatures were not significantly changed during
the two-day post-treatment observation (36.44°C ± 0.24
versus 36.5°C ± 0.22, n = 15, P=0.35). No changes were
observed in blood cell count or temperature at the 12-
week follow-up.
CB-SCs are tightly adherent [9,16] and not expected
to escape the device. To confirm CB-SCs are completely
retained in the Educator and not transferred to the
patient, we examined cells leaving the device to check
for SSEA-3, a CB-SC-specific marker. Flow cytometry
confirmed the absence of SSEA-3 in cells leaving the
Educator (Additional file 1: Figure S1). These data indi-
cate that the cells returned to the patients are autolo-
gous. Additionally, HLA matching is not required prior
to Stem Cell Educator therapy because CB-SCs are not
transferred to the patient and because CB-SCs have very
low immunogenicity [9,13,16]. Thus, Stem Cell Educator
therapy is a very safe approach.
Table 1 Characteristics of the T1D subjects before treatment
Patient
No.
Age Gender Marriage History
(year)
Height
(cm)
Body
weight
(kg)
C-peptide
(ng/ml)*
Auto-Antibodies HbA1C
(%)
Insulin dose
(U/day)
IA-2A GAD ICA IAA
Group A: Long-standing patients having some residual islet b cell function and received therapy with CB-SC
1 17 F No 5 145 35 0.30 - + - - 12.3 52
2 23 F No 5 167 59 0.56 - + - - 6.6 50
3 38 F Yes 11 160 60 0.12 - + - - 7.3 23
4 39 F Yes 1 156 49 0.636 + + + - 11.3 22
5 31 M Yes 14 170 70 0.18 + + - - 6.5 30
6 30 M Yes 2 182 70 0.18 - + - - 8.4 40
Mean
(SD)
30
(9)
6
(5)
163
(12.7)
57
(13.4)
0.33
(0.22)
8.7
(2.5)
36.2
(13.2)
Group B: Long-standing severe patients with no residual islet b cell function and received therapy with CB-SC
7 40 M Yes 17 170 72.5 0.01 - + - - 8.8 48
8 15 F No 5 163 65 0.01 - + - - 15.5 50
9 21 F No 4 168 65 0.01 + - - - 9.9 46
10 23 F No 12 162 80 0.01 + + + - 16.5 60
11 40 F Yes 21 160 67 0.01 + - - - 8.6 37
12 21 F No 5 157 56 0.01 - + - - 13.6 50
Mean
(SD)
27
(11)
11
(7)
163
(4.9)
67.6
(8.1)
0.01
(0)
12.2
(3.5)
48.5
(7.4)
Control group: Long-standing patients having some residual islet b cell function and received sham therapy
13 35 M Yes 1 178 73.5 0.37 + - + - 9.8 30
14 41 M Yes 14 165 65 0.55 - + - - 6.4 48
15 24 M No 3 175 58 0.3 - + - - 10.7 48
Mean
(SD)
33
(9)
6
(7)
173
(6.8)
65.5
(7.8)
0.41
(0.13)
9.0
(2.3)
42
(10.4)
*The level of 0.01 ng/ml is the minimum detectable level (sensitivity) of C-peptide by radioimmunoassay (RIA). To convert C-peptide value to nmol/L, multiply the
ng/ml by 0.331.
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Participants in Group A (that is, those with moderate
T1D and some residual b cell function) exhibited
improved fasting C-peptide levels at 12 and 24 weeks
post-treatment (Figure 2A and 2B, Table 2), and partici-
pants in Group B (that is, those with severe T1D and no
residual pancreatic islet b cell function) exhibited suc-
cessive improvement in fasting C-peptide levels at each
follow-up (Figure 2A and 2C, Table 2). C-peptide
response following a 75-g oral glucose tolerance test
(OGTT) improved among Group A participants at 4
and 12 weeks (Figure 2B). Notably, participants in
Group B exhibited essentially no C-peptide production
following glucose challenge at baseline (that is, less than
the minimum sensitivity of 0.01 ng/ml at all time
points) but demonstrated marked improvement at 12
weeks (Figure 2C, Table 2). Improvement was main-
tained through the final follow-up (that is, 40 weeks
post-treatment; P=0.026) (Figure 2C). Participants in
the Control Group did not exhibit significant change at
any follow-up (Figure 2A, Table 2).
Consistent with improved b cell function, the median
daily dose of insulin was reduced 38% at 12 weeks post-
treatment in Group A (36 ± 13.2 units/day at baseline ver-
sus 22 ± 1.8 units/day 12 weeks post-treatment) and 25%
in Group B (48 ± 7.4 units/day at baseline versus 36 ± 4.4
units/day 12 weeks post- treatment), but no change was
observed in the Control Group. The reduced daily dose of
Figure 2 Improvement of b-cell function by Stem Cell Educator therapy.( A) Fasting C-peptide levels of T1D participants over 24 weeks.
Group A and Group B participants (n = 6 per group) received one Stem Cell Educator treatment. Control group participants (n = 3) received
sham therapy (no CB-SCs in the Stem Cell Educator). (B) 12-week follow-up C-peptide levels after OGTT at 2 hours in Group A T1D subjects with
some residual b cells. (C) Comparison of C-peptide levels at glucose challenge after 40-week follow-up in Group B T1D subjects. The dashed red
line indicates the lower limit for normal C-peptide levels in Chinese populations. The dashed purple line indicates the minimum detectable level
(sensitivity) of C-peptide by radioimmunoassay (RIA). CB-SCs, cord blood stem cells; OGTT, oral glucose tolerance test; T1D, type 1 diabetes.
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follow-up for this measure (24 weeks). The median gly-
cated hemoglobin (HbA1C) in Group A was significantly
lowered from 8.73% ± 2.49 at baseline to 7.67% ± 1.03 at 4
weeks post-treatment (P=0.036) and to 6.82% ± 0.49 at
12 weeks post-treatment (P=0.019). The median HbA1C
in Group B was reduced 1.68% ± 0.42 at 12 weeks post-
treatment, but no change was observed in the Control
Group (9.0% ± 2.3 at baseline versus 8.7% ± 1.9 at 12
weeks post-treatment, P=0.86). Thus, the ex vivo immune
education of CB-SC leads to regeneration of islet b cells
and improvement of b cell function in long-standing T1D
subjects.
Efficacy outcomes in autoimmune control
Next, we explored mechanisms underlying CB-SC-
mediated immune modulation. Regulatory T lymphocytes
(Tregs) play a crucial role in maintaining homeostasis and
self-tolerance by inhibiting the action of autoreactive effec-
tor T cells [14,19,20], but previous attempts to manipulate
Tregs for clinical applications have been problematic [21].
We measured changes in the percentage of CD4
+CD25
+
Foxp3
+ Tregs in peripheral blood of participants following
Stem Cell Educator treatment. The percentage of Tregs in
peripheral blood of participants was significantly increased
4 weeks after Stem Cell Educator therapy (Figure 3A),
whereas the percentage of Tregs in peripheral blood of
participants receiving sham therapy was unchanged from
baseline (Figure 3A). TGF-b1 has also been implicated in
Treg-mediated immune suppression [22] as well as in
maintenance of self-tolerance in T1D animal models sub-
jected to stem cell-mediated immune modulation
[9,15,23]. We examined TGF-b1 and IL-10 expression to
explore whether these pathways are activated following
Stem Cell Educator therapy. Participants in the treatment
group exhibited significant increases in plasma level of
TGF-b1 at the 4-week follow-up (P =0 . 0 0 1 ,F i g u r e3 B )
but did not exhibit changes in the plasma level of IL-10
(P = 0.44, Figure 3B). Both TGF-b1a n dI L - 1 0f a i l e dt o
show changes in the control group.
We also examined levels of CD28 [24-28] and induci-
ble costimulator (ICOS) [29,30], which are essential for
the establishment, maintenance and efficacy of Tregs
[24-32]. Flow cytometry revealed an increase in CD28
and ICOS in lymphocytes 4 weeks after Stem Cell Edu-
cator therapy (Figure 3C), but levels of both molecules
Table 2 Changes in C-peptide levels of the T1D subjects after treatment at 12 weeks.
Patient No. C-peptide (ng/ml) Changes in C-peptide levels (ng/ml)
Group A:
1 0.56 ↑ 0.26
2 0.98 ↑ 0.42
3 0.54 ↑ 0.42
4 1.1 ↑ 0.46
5 0.52 ↑ 0.34
6 0.78 ↑ 0.60
Mean 0.75 ↑ 0.42
(SD) (0.24) (0.12)
Group B
7 0.25 ↑ 0.24
8 0.11 ↑ 0.10
9 0.28 ↑ 0.27
10 0.43 ↑ 0.42
11 0.11 ↑ 0.10
12 0.12 ↑ 0.11
Mean 0.22 ↑ 0.21
(SD) (0.13) (0.13)
Control Group
13 0.41 ↑ 0.04
14 0.38 ↓ 0.17
15 0.35 ↑ 0.05
Mean 0.38 ↓ 0.03
(SD) (0.03) (0.12)
Levels of plasma C-peptide before treatment served as baseline for comparison. The level of C-peptide was increased (↑); the level of C-peptide was decreased (↓).
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(Figure 3C). We also noted other changes at the 4-week
f o l l o w - u pc o n s i s t e n tw i t hi m p r o v e dh e l p e rTc e l l1
(Th1) and Th2-mediated immune function (Figure 3D).
Expression of IL-4 and IL-12 was significantly increased
(P =0 . 0 1 6a n dP = 0.0093, respectively) and expression
of IL-5 and IL-13 was decreased (P = 0.00039 and P =
0.00206, respectively). The production of pro-inflamma-
tory IL-17A was also decreased 4 weeks after treatment
(Figure 3D, P = 0.0043). No changes were observed in
levels of these cytokines in participants who received
sham therapy (Additional file 1: Figure S2).
Autoimmune regulator (Aire), usually expressed in
thymic medullary epithelial cells, plays an important
role in immune tolerance by mediating ectopic expres-
sion of peripheral self-antigens and mediating the dele-
tion of auto-reactive T cells [33,34]. We found that
CB-SCs express Aire (Figures 4A and 4B). To deter-
m i n et h eA i r ef u n c t i o ni nC B - S C ,w eu s e dt h r e ep a i r s
of human Aire-specific small interfering RNAs (siRNA)
Figure 3 Markers of immune function in T1D patients after Stem Cell Educator therapy. Patient lymphocytes were isolated from
peripheral blood by Ficoll-Hypaque (g = 1.077) for flow cytometry analyses in T1D patients at baseline and 4 weeks after Stem Cell Educator
therapy. Isotype-matched IgG served as control. (A) Flow Analysis of CD4
+CD25
+Foxp3
+ Tregs demonstrating an increase in the percentage of
Tregs at 4 weeks post-treatment. (B) Cytokine ELISAs demonstrating an increase in TGF-b1 but not IL-10 at 4 weeks post treatment. (C) Flow
cytometry on co-stimulating molecules indicating increases in CD28 and ICOS at 4 weeks post-treatment with Stem Cell Educator therapy (top
panels). Control group failed to show increases (bottom panels). (D) Flow analysis of intra-cellular cytokines demonstrating differential effects on
key interleukins at 4 weeks post-treatment. Data are representative of preparations from all T1D participants (n = 12) that received Stem Cell
Educator therapy. ELISA, enzyme-linked immunosorbent assay; ICOS, inducible costimulator; IgG, immunoglobulin G; IL10, interleukin 10; T1D,
type 1 diabetes; Tregs, regulatory T cells.
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blots confirmed knockdown of Aire protein expression
(Figure 4C) and a corresponding reduction in the
expression of programmed death ligand-1 (PD-L1) that
contributes to the immune modulation of CB-SC
[13,35] (Figure 4D). Knockdown of Aire also reduced
the percentage of Tregs in the co-cultured lymphocyte
population (P=0.028) (Figure 4E). The data indicate
that Aire is involved in immune modulation and induc-
tion of immune tolerance following Stem Cell Educator
therapy.
Discussion
The present studies demonstrate the safety and thera-
peutic efficacy of Stem Cell Educator therapy in T1D
patients. The device, essentially a stack of specially-
designed Petri dishes with adherent CB-SCs, functions
as part of a closed-loop system that circulates a patient’s
blood through a blood cell separator, briefly co-cultures
the patient’s lymphocytes with CB-SCs in vitro,a n d
returns the educated lymphocytes to the patient’s circu-
lation. Through secreted and cell-surface signaling mole-
cules, the CB-SCs educate the lymphocytes passing
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Figure 4 Characterization of Aire in CB-SC.( A) Expression of Aire mRNA in CB-SCs. Real time PCR analysis for Aire mRNA expression followed
by electrophoresis in 2% agarose gel. Data are representative of three CB-SC preparations. (B) Immunocytochemistry for Aire. Isotype-matched
IgG served as control (left) for Aire staining (right) with magnification ×200. (C) Western blot shows the dose-dependent knockdown response of
Aire following siRNA treatment. (D) Effects of Aire knockdown on PD-L1. Western blot demonstrates decreased expression of program death
ligand-1 (PD-L1) in CB-SC following knockdown of Aire expression by siRNA. CB-SC cells transfected with negative control siRNA (NC siRNA)
served as control for three pairs of human Aire-specific siRNA (P1, P2, and P3) at optimal concentration (50 nM). Representative data of those
obtained from five experiments. (E) Effects of Aire knockdown on co-cultured lymphocytes. Flow analysis of Treg population following culture of
lymphocytes alone, in the presence of phytohaemagglutinin (PHA, 10 μg/ml), in the presence of PHA and NC siRNA-treated CB-SCs, and in the
presence of PHA and Aire siRNA (50 nM)-treated CB-SCs. Representative data obtained from three experiments. Aire, autoimmune regulator; CB-
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patients are autologous lymphocytes that have been
treated (or educated) by CB-SCs. The Stem Cell Educa-
tor therapy requires only two venipunctures, carries a
lower risk of infection than a typical blood transfusion,
and does not introduce stem cells or reagents into
patients. In addition, CB-SCs have very low immuno-
genicity, eliminating the need for human leukocyte anti-
gen (HLA) matching prior to treatment [9,13,16]. Thus,
this innovative approach may provide CB-SC-mediated
immune modulation therapy for multiple autoimmune
diseases while mitigating the safety and ethical concerns
associated with other approaches [4,11,21,36]. The rela-
tive simplicity of the approach may also provide cost
and time savings relative to other approaches.
R e s u l t sf r o mt h i st r i a lc o n f i r m prior studies indicating
that the adherence of CB-SCs could be exploited to
develop therapies that do not introduce the CB-SCs into
the patient [9,14]. Furthermore, the trial confirms our
expectation that co-culturing patient lymphocytes with
CB-SCs alters the patient’s immune response and leads
to clinically relevant improvement in the autoimmune
process. Previous studiest h a th a v ed e m o n s t r a t e d
improved metabolic control in T1D have usually been
limited to new- or recent-onset participants with residual
b cell function [36-38], but this study demonstrates that
Stem Cell Educator therapy is effective both in T1D with
and without residual b cell function. Although we were
not able to directly evaluate the status of islets or b cells
through histological examination in this study, previous
studies have demonstrated that patients with long-stand-
ing, severe T1D have lost all islets due to infiltration of
autoimmune cells [39]. Thus, the successive improve-
ment we observed in C-peptide levels (both fasting and
OGTT) following Stem Cell Educator therapy suggests
improvement in the number and/or function of islet b
cells. The improvement of islet b cell function in T1D
patients with residual islet b cells is impressive, but the
recovery of islet b cell function in T1D patients without
evident b cell function prior to treatment indicates Stem
Cell Educator therapy addresses the underlying challenge
of autoimmunity and controls the immune response suf-
ficiently to allow regeneration of the native b cell popula-
tion. Thus, this trial provides powerful evidence that
exposing a patient’s lymphocytes to CB-SCs can achieve
the two essential outcomes required to cure T1D: rever-
sal of autoimmunity and regeneration of islet b cells.
However, longer post-treatment observations with larger
samples are needed.
Importantly, the trial provides additional support for
the mechanisms of CB-SC-mediated immune modulation
and demonstrates that these mechanisms are apparent
and lasting in patients. Specifically, the trial provides evi-
dence that CB-SCs in the device educate effector T cells
and/or Tregs, resulting in lasting changes in the expres-
sion of costimulating molecules, increasing the popula-
tion of Tregs, and restoring Th1/Th2/Th3 cytokine
balance, each of which is expected to improve control of
autoimmunity of T1D [14,40]. Therapy also increases
production of TGF-b1 in plasma of T1D subjects, one of
the best-characterized cytokines contributing to the
induction of peripheral immune tolerance [23]. Results
from a NOD mouse study [14] demonstrated that
increased plasma TGF-b1 may contribute to the forma-
tion of a ‘TGF-b1r i n g ’ around pancreatic islets that pro-
tects b cells against infiltrating lymphocytes, providing a
safe environment for promotion of b cell regeneration
[14,15]. Due to the limitation of obtaining pancreatic tis-
sues from human subjects, evidence from our trial indi-
cates that b cell regeneration occurs even in patients who
do not appear to have b cells prior to treatment. CB-SCs
f r o mt h ed e v i c ea r en o tl i k e l yt ob et h es o u r c eo ft h i s
regeneration because they are not transferred to the
patient during therapy. As demonstrated in other studies,
the regenerated cells may be derived from multiple endo-
genous resources such duct cells, a cells [11,41], and per-
ipheral blood-derived insulin-producing cells [42].
Further studies may provide additional insight into the
role of TGF-b1i nb cell regeneration and the source of
regenerated cells in T1D patients without functional b
cell populations.
Conclusions
In conclusion, findings from this study demonstrate the
feasibility and safety of Stem Cell Educator therapy and
demonstrate that T1D patients achieve improved meta-
bolic control and reduced autoimmunity that lasts
months following a single treatment. Further improve-
ment may be achieved with additional treatments. Nota-
bly, our clinical data provide powerful evidence that
reversal of autoimmunity leads to regeneration of islet b
cells and improvement of metabolic control in long-
standing T1D subjects. This principle may also be benefi-
cial in the treatment of other autoimmune-related
diseases.
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